Watch Europe’s Rising Biotech Startups Battle it out at Refresh

After the early stage startups gave it all on stage, it was the turn of the more advanced biotechs to fight each other at Labiotech Refresh 2017. 

The first contestant was Beroceutica, a startup from Germany that uses artificial intelligence to look for biomarkers that allow better patient stratification in clinical trials. The goal is to increase the success rate in clinical trials, which could also save a lot of money. The applications could benefit patients suffering from difficult to treat diseases such as Alzheimer’s and cancer.

Then came Nova Discovery, which is specialized in in silico clinical trials. Its technology explores large volumes of multi-omics and clinical data can be used to predict the efficacy of a new therapy before it goes into an expensive trial in order to help make the right decisions early in the R&D process.

The winner was Confo Therapeutics, which stole the show with its GPCR platform. As a target, GPCRs already take up 30% of the drug market, but 80% of them haven’t been drugged due to their instability in vitro. Confo uses single domain antibodies called confobodies to lock GPCRs into stable conformations that can be easily drugged.

Startup Battle Labiotech Refresh 2017 Confo Therapeutics

Christel Menet, CSO of Confo Thx, receiving the winning prize

If you’d like to be part of the next Refresh Startup Battle, stay tuned for updates about next year’s event!

The early-stage startup battle at Refresh 2017 was sponsored by

Logo_Vibrant_Magenta_RGB

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.